DDrare: Database of Drug Development for Rare Diseases

227. オスラー病
［臨床試験数：49，薬物数：69（DrugBank：21），標的遺伝子数：23，標的パスウェイ数：132］

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AVASTIN; AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung; Acetate; Avastin; BEVACIZUMAB; Bevacizumab; Bevacuzimab spray; Blood samples; Chloride; Dicynone; Doxycycline; Doxycycline Hyclate; EMEA/H/C/000712; ETAMSYLATE; Estriol; Etamsylate; Ferrous sulphate 200mg oral tablet; Floseal; Gold; Itraconazole; Mupirocin; NINTEDANIB; NaCl; Nintedanib; Nintédanib; OCTREOTIDE; OCTREOTIDE ACETATE; OFEV; Octreotide; Octreotide LAR; Other: Epistaxis charts; Other: Packing; Other: Standard Treatment; Other: Standard care; PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung; Pazopanib; Pegylated Interferon Alpha2b; Pomalidomide; Pomalidomide Oral Product; Propranolol; Propranolol treatment; RVG 18236; Ranibizumab; SODIUM CHLORIDE; SUB16402MIG; Sandostatin LAR; Sandostatin LAR 20 mg; Sclerotherapy; Sodium chloride; Soy protein isolate; Sporanox; Sterile saline; Submucosal Bevacizumab; THALIDOMIDE; THALIDOMIDE CELGENE*28CPS 50MG; TIMOLOL MALEATE; Tacrolimus; Tacrolimus (Advagraf); Tacrolimus capsule (low-dose); Tamoxifen; Thalidomide; Timolol; Timolol Alcon 0.5% collyre; Timolol Gel; Timolol nasal spray; Topical timolol maleate; Tranexamic Acid; Tranexamic acid; Vit D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01485224 (ClinicalTrials.gov)	November 2011	28/11/2011	Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia	Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	Hereditary Hemorrhagic Telangiectasia;Epistaxis	Drug: Thalidomide	IRCCS Policlinico S. Matteo	NULL	Completed	18 Years	N/A	All	31	Phase 2	Italy
2	EUCTR2011-004096-36-IT (EUCTR)	11/10/2011	19/03/2012	Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasia	Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT)	Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia MedDRA version: 14.1;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]	Trade Name: THALIDOMIDE CELGENE*28CPS 50MG INN or Proposed INN: THALIDOMIDE	OSPEDALE POLICLINICO S. MATTEO	NULL	Not Recruiting			Female: yes Male: yes	31	Phase 2	Italy
3	NCT00389935 (ClinicalTrials.gov)	October 2006	17/10/2006	Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding	Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding	Arteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;Melena	Drug: Thalidomide	Northport Veterans Affairs Medical Center	Georgia Regents University;University of Massachusetts, Worcester	Completed	18 Years	N/A	Both	14	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01485224
(ClinicalTrials.gov)

November 2011

28/11/2011

Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia

Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia;Epistaxis

Drug: Thalidomide

IRCCS Policlinico S. Matteo

NULL

Completed

18 Years

N/A

All

Phase 2

Italy

EUCTR2011-004096-36-IT
(EUCTR)

11/10/2011

19/03/2012

Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasia

Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT)

Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia
MedDRA version: 14.1;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

Trade Name: THALIDOMIDE CELGENE*28CPS 50MG
INN or Proposed INN: THALIDOMIDE

OSPEDALE POLICLINICO S. MATTEO

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Italy

NCT00389935
(ClinicalTrials.gov)

October 2006

17/10/2006

Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding

Arteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;Melena

Drug: Thalidomide

Northport Veterans Affairs Medical Center

Georgia Regents University;University of Massachusetts, Worcester

Completed

18 Years

N/A

Both

Phase 2

United States